PD-1 Blockade and CDK4/6 Inhibition Augment Nonoverlapping Features of T Cell Activation in Cancer

Scientists performed single-cell RNA-sequencing and T cell receptor clonotype tracking of breast and ovarian cancer patients treated with the CDK4/6 inhibitor ribociclib and PD-1 blockade.
[Journal Of Experimental Medicine]
Full Article

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News